Endeavor BioMedicines Stock
HealthTechLooking to sell Endeavor BioMedicines stock or options?
Endeavor BioMedicines, a clinical-stage organization, is dedicated to creating innovative therapies that target the root causes of pulmonary fibrosis. The company is researching a small-molecule inhibitor, which holds promise for the treatment of idiopathic pulmonary fibrosis (IPF). This inhibitor could potentially stop, and even reverse, the progression of IPF. Endeavor BioMedicines enables healthcare professionals to concentrate on precision treatments for terminal diseases, thereby improving patient well-being and longevity.
Avidity Partners, Omega Funds, Eckuity, Piper Sandler, Ally Bridge Group, Woodline Partners, CE-Ventures, The Invus Group, Abrdn, Fidelity Management & Research, Perceptive Advisors, Velosity Capital, Longitude Capital, Silver Arch Bio, Matrix Capital Management, Revelation Partners, T. Rowe Price Group, SymBiosis Capital Management.